PITPNM3 (phosphatidylinositol transfer protein 3) functions as a membrane-associated protein that catalyzes phospholipid transfer between membranes and serves as a functional receptor for the chemokine CCL18 1. The protein mediates CCL18-induced signaling cascades that promote cancer metastasis through multiple mechanisms. Upon CCL18 binding, PITPNM3 activates intracellular calcium signaling and forms complexes with Pyk2 kinase, leading to Src kinase activation and integrin clustering 12. This signaling cascade enhances cancer cell adherence to extracellular matrix, migration, invasion, and epithelial-mesenchymal transition (EMT) 3. PITPNM3 also activates NF-κB signaling pathways, promoting the production of pro-metastatic cytokines IL-6 and IL-8 43. The clinical significance of PITPNM3 is substantial, as its expression correlates with tumor metastasis, poor differentiation, and chemotherapy resistance in multiple cancer types including breast and hepatocellular carcinomas 13. Recent therapeutic developments include PITPNM3-selective small molecule inhibitors that effectively reduce cancer metastasis in preclinical models, establishing PITPNM3 as a promising therapeutic target for metastatic cancers 5.